On April 1, 2024, Akanda Corp. (NASDAQ: AKAN) ("Akanda"), an international medical cannabis company, completed the transaction with SOMAÍ Pharmaceuticals Ltd. for the sale of RPK, its indirect wholly-owned Portuguese subsidiary. Pursuant to the provisions set forth in the definitive share purchase agreement, the cash purchase price is USD $2,000,000. 
 
Akanda is an international medical cannabis and wellness platform company seeking to help people lead better lives through improved access to high quality and affordable products. SOMAÍ Pharmaceuticals is a leading EU-GMP European pharmaceutical and biotech company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceuticals portfolio.
 
Gowling WLG advised Akanda Corp. in this transaction with a team which included Peter Simeon and Sharagim Habibi.